From 2003 until late 2025, every estrogen product sold in the US, including low-dose vaginal creams, tablets and rings, carried the FDA's highest-level boxed warning listing stroke, blood clots, probable dementia, cardiovascular disease and breast cancer.
That warning was based on data from systemic oral estrogen-plus-progestin therapy, not on data about local, low-dose vaginal estrogen, which is absorbed into the bloodstream in only minimal amounts. A large observational study of over 45,000 women found vaginal estrogen users had no increased risk of stroke, breast cancer, colorectal cancer, endometrial cancer or blood clots, and among women with a uterus, users actually had lower rates of several serious outcomes. On November 10, 2025, the FDA and HHS removed the boxed warning specifically from low-dose vaginal estrogen products, a decision The Menopause Society said it agreed with. The endometrial cancer warning is still kept on systemic estrogen-alone products, so it's worth being clear that local and systemic hormone therapy carry different risk profiles.
Whether the old class-wide warning was ever scientifically justified for local vaginal estrogen is now essentially settled against it. The genuinely live question is whether loosening the warning across systemic hormone products in the same move went too far, since systemic and vaginal-only products carry different risk profiles.
What the research shows, and which source each finding rests on
From 2003 to late 2025, every estrogen product in the US, including low-dose vaginal creams, tablets and rings, carried the FDA's highest-level boxed warning derived from systemic oral estrogen-plus-progestin data.
In the Women's Health Initiative Observational Study of 45,663 women followed a median of 7.2 years, vaginal estrogen users had no increased risk of stroke, invasive breast cancer, colorectal cancer, endometrial cancer or venous thromboembolism; among women with a uterus, users had lower risk of coronary heart disease, fracture, all-cause mortality and a combined risk index (adjusted HR 0.68, 95% CI 0.55-0.86).
On November 10, 2025, HHS and the FDA announced removal of the boxed warning from low-dose vaginal estrogen, following a comprehensive literature review, a July 2025 FDA expert panel and public comment; the endometrial cancer boxed warning was retained for systemic estrogen-alone products; the first revised product labels were approved February 12, 2026.
Where the real disagreement is
Each position is shown with its own sources. A position listed here is not necessarily the accepted view.
The old warning was never evidence-based for vaginal products
Rachel Rubin, Kelly Casperson, JoAnn Manson, The Menopause Society and most professional societies by 2025
The warning extrapolated systemic oral data to a therapy with minimal systemic absorption; safety data showed no elevated risk, and the label scared women and clinicians away from a safe therapy.
Class labeling was the conservative default
The FDA's pre-2025 position
No long-term randomized trials of vaginal estrogen exist for hard endpoints like stroke or cancer, and a 2018 FDA denial of a citizen petition kept the class-wide warning in place until the 2025 review.
What would settle it: For local vaginal estrogen, the November 2025 label change has effectively settled the question; the residual debate is whether systemic hormone therapy risk, which is age- and timing-dependent, was adequately distinguished in the same announcement.
What is really going on here
- I keep getting UTIs and antibiotics - why has no one offered vaginal estrogen?
- The label says stroke, cancer, dementia, so vaginal estrogen must be dangerous - is that framing accurate now?
- The FDA removed all the warnings, so hormones are risk-free now - is that accurate?
Questions for your doctor
- Has the current label on the vaginal estrogen product you're prescribing been updated since November 2025?
- How is the risk profile of local vaginal estrogen different from systemic hormone therapy?
- If I was previously told not to use vaginal estrogen because of the old label, can we revisit that?
- Are there any personal risk factors that would still make vaginal estrogen inadvisable for me?
Questions with no answer yet
Now that the boxed warning is removed, will actual prescribing and use rates among eligible women rise to match the new label, or will the years of accumulated fear from patients and clinicians trained under the old warning persist regardless of the label change?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: The old warning measurably suppressed use, with women declining to fill or use prescriptions specifically because of the label, but there is no report yet of post-2025 utilization data showing whether removal of the warning actually changed real-world prescribing or usage rates.
What would test it: Prescribing and usage data collected in the years following the November 2025 label change, compared against pre-change baseline rates.
Did loosening the boxed warning across systemic hormone products in the same regulatory action, not just on local vaginal products, appropriately distinguish the very different risk profiles of local and systemic therapy, or did it risk blurring that distinction for patients and clinicians?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: This is described as the genuinely live residual question, since systemic hormone therapy risk is age- and timing-dependent, and some organizations issued a celebrating-but-cautioning response to the broader label change.
What would test it: Research tracking whether patient and clinician understanding of the distinction between local and systemic hormone therapy risk changes, for better or worse, in the years following the label update.
For the large observational safety study behind the label change, how much of the reassuring finding, no increased risk and some outcomes actually lower in vaginal estrogen users, could be explained by healthier women being more likely to seek out and use vaginal estrogen in the first place?
Partly studiedWhat is known: For a related breast cancer survival study, healthy-user bias is explicitly flagged as possible, and the finding is cautioned against being read as protection. The same design limitation applies to any observational safety study of this kind, though a dedicated bias-adjustment analysis for the main safety cohort is not reported.
What would test it: Statistical methods designed to detect and adjust for healthy-user bias, such as comparing users and non-users matched on baseline health-seeking behavior, applied specifically to the main safety cohort.
Sources
- 1.FDA/HHS boxed-warning removal announcement, coverage via Harvard HealthReview, opinion or mechanism
- 2.Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study.Crandall CJ, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the WHI Observational Study. Menopause 2018;25(1):11-20 · Observational study
- 3.The Menopause Society press release on the FDA announcementReview, opinion or mechanism
The letter grades the type of study behind a claim, not the answer itself.
This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.
You are not imagining it
In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.
Start Free MappingRelated questions
- What is GSM (genitourinary syndrome of menopause) and why does it affect both my vagina and my bladder?
- Can I use vaginal estrogen if I've had breast cancer?
- I keep getting UTIs after menopause and keep getting put on antibiotics - can vaginal estrogen actually help?
- Sex has become painful since perimenopause - is this just something I have to live with?
- What is vaginal DHEA (prasterone) and how is it different from vaginal estrogen?
- What is ospemifene, the daily pill for painful sex, and how does it work?
- Back to topic: Vaginal, sexual and urinary health